Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2026)

Roivant Sciences (ROIV) has reported Other Accumulated Expenses for 6 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses fell 93.55% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.2 million (down 93.55% YoY), and the FY2026 full-year result was $583000.0, down 50.09% from the prior year.
• Other Accumulated Expenses advanced to $3.2 million in Q2 2026 per ROIV's latest filing, from $583000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $76.3 million in Q1 2023 and bottomed at $583000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $39.1 million across 5 years, with a median of $48.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses surged 1940.32% in 2022, then slumped 97.38% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $56.3 million in 2022, then dropped by 22.55% to $43.6 million in 2023, then gained by 22.55% to $53.5 million in 2024, then plunged by 80.84% to $10.2 million in 2025, then slumped by 68.63% to $3.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $3.2 million, $583000.0, and $10.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.